Question 1

What is DualityBio?

Accepted Answer

DualityBio is a Entity.

Question 2

How often does DualityBio appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was DualityBio first tracked by Ergen?

Accepted Answer

First tracked on Apr 11, 2026.

Question 4

When was DualityBio last mentioned in news?

Accepted Answer

Last active on May 14, 2026.

Question 5

What is DualityBio's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is DualityBio in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving DualityBio?

Accepted Answer

BioNTech Trastuzumab Pamirtecan Phase 2 Success (Apr 11, 2026, 7 articles).

Question 8

How did the "BioNTech Trastuzumab Pamirtecan Phase 2 Success" event impact DualityBio?

Accepted Answer

DualityBio is co-developing trastuzumab pamirtecan with BioNTech, and the positive Phase 2 results validate its Duality Immune Toxin Antibody Conjugates (DITAC) platform, enhancing its reputation and potential for future collaborations or public offering.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.